DURECT to Present at the BMO Capital Markets Healthcare Conference
CUPERTINO, Calif., July 28 /PRNewswire-FirstCall/ -- DURECT
Corporation (NASDAQ:DRRX) announced today that Matthew
Hogan, Chief Financial Officer, will be presenting at the BMO
Capital Markets 9th Annual Focus on Healthcare Conference on
Wednesday, August 5 at 4:00 pm Eastern Time. The conference is
being held at the Millennium Broadway Hotel in New York City. A
webcast of the presentation will be accessible at: http://www.bmocm.com/conferences/2009healthcare/webcast/.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) About DURECT Corporation
DURECT is an emerging specialty pharmaceutical company
developing innovative drugs for pain and other chronic diseases,
with late-stage development programs including REMOXY ,
POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's
proprietary oral, transdermal and injectable depot delivery
technologies enable new indications and superior
clinical/commercial attributes such as abuse deterrence, improved
convenience, compliance, efficacy and safety for small molecule and
biologic drugs. For more information, please visit
www.durect.com.
NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and
ELADUR(TM) are trademarks of DURECT Corporation. Other referenced
trademarks belong to their respective owners. REMOXY, POSIDUR,
ELADUR and TRANSDUR-Sufentanil are drug candidates under
development and have not been approved for commercialization by the
US Food and Drug Administration or other health authorities.
Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
Source: DURECT Corporation
CONTACT: Matthew J. Hogan, Chief Financial Officer of
DURECT
Corporation, +1-408-777-4936
Web Site: http://www.durect.com/
Posted: July 2009
